MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Bolder Surgical, a privately held, U.S.-based company that provides advanced energy vessel sealing surgical devices.
“The acquisition of Bolder Surgical will expand Hologic’s growing laparoscopic portfolio and underscores our commitment to women’s health,” said Essex Mitchell, Hologic’s Division President, Surgical. “We will better serve our existing physician base with Bolder’s minimally invasive treatments and advanced vessel sealing technology.”
The transaction adds laparoscopic vessel sealing, dividing, and dissecting devices to the Hologic Surgical portfolio, and will also enable Hologic to expand the use of Bolder’s devices to OB/GYN specialists. All Bolder devices including the CoolSeal® Vessel Sealing Suite, JustRight® 3 mm vessel sealer and JustRight® 5 mm stapler, will immediately join the Hologic Surgical portfolio.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, CoolSeal, JustRight, and the Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
This news release contains forward-looking information that involves risks and uncertainties, including statements about Hologic’s and Bolder’s plans, objectives, expectations, and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; each company’s strategies, positioning, resources, capabilities, and expectations for future performance; and each company’s outlook and financial and other guidance. These forward-looking statements are based upon assumptions made as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.
Risks and uncertainties that could adversely affect either company’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the possibility that the anticipated benefits from the proposed transaction cannot be fully realized or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Bolder Surgical’s operations with those of Hologic will be greater than expected; the ability of Hologic and Bolder Surgical to retain and hire key personnel; the coverage and reimbursement decisions of third-party payers and the guidelines, recommendations, and studies published by various organizations relating to the use of products and treatments; the ability to successfully manage ongoing organizational and strategic changes, including Hologic’s ability to attract, motivate and retain key employees; the development of new competitive technologies and products; regulatory approvals and clearances for products; the anticipated development of markets in which products are sold into and the success of products in these markets; the anticipated performance and benefits of products; estimated asset and liability values; anticipated trends relating to Hologic’s financial condition or results of operations; and Hologic’s capital resources and the adequacy thereof.
The risks included above are not exhaustive. Other factors that could adversely affect Hologic’s business and prospects are described in Hologic’s filings with the SEC. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
SOURCE: Hologic, Inc.